Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond

References

• Abraham , J. 2003 . The Science and Politics of Medicines Control . Drug Safety , 26 : 135 – 143 .
   Google Scholar
• American Public Health Association ( 2003 ) Supporting Legislation for Independent Post-marketing (Phase IV) Comparative Evaluation of Pharmaceuticals . APHA Policy Statement 2003-1 . Accessed 7 May 2006, available at http://apha.org/legislative/policy/2003/2003-001.pdf
   Google Scholar
• Avorn , J. 2005 . FDA Standards: Good Enough for Government Work? . New England Journal of Medicine , 353 : 969 – 972 .
   Google Scholar
• Bates , D.W. , Cullen , D.J. , Laird , N. , Petersen , L.A. , Small , S.D. Servi , D. 1995 . Incidence of Adverse Drug Events and Potential Adverse Drug Events, Implications for Prevention . Journal of American Medical Association , 274 : 29 – 34 .
   PubMed Web of Science ®Google Scholar
• Bates , D.W. , Spell , N. , Cullen , D.J. , Burdick , E. , Laird , N. Petersen , L.A. 1997 . The Cost of Adverse Events in Hospitalized Patients . Journal of American Medical Association , 277 : 307 – 311 .
   PubMed Web of Science ®Google Scholar
• Biriell , D. and Edwards , J.R. 1997 . Reasons for Reporting Adverse Drug Reactions—Some Thoughts Based on an International Review . Pharmacoepidemiology Drug Safety , 6 : 21 – 26 .
   PubMed Web of Science ®Google Scholar
• Central Intelligence Agency ( 2005 ) Zambia. The World Factbook . Accessed July 2005, available at http://www.cia.gov/cia/publications/factbook/geos/za.html
   Google Scholar
• Central Statistics Office ( 2002 ) Zambia Demographic and Health Survey ( Government Printers : Lusaka ).
   Google Scholar
• Chikwenya , N. , Mtonga , S. , Bwembya , M. , Andala , R. , Chansa , C. , Broms , C. et al. . ( 2004 ) Proposal to Establish a Drug Supply Account: Towards Financial Sustainability for Drugs and Laboratory Supplies in the Public Health Sector . Government of Republic of Zambia, Ministry of Health .
   Google Scholar
• Classen , D.D. , Pestonik , S.L. , Evans , R.S. , Lloyd , J.F. and Burke , J.P. 1997 . Adverse Events in Hospitalized Patients: Excess Length of Stay, Extra Costs and Attributable Mortality . Journal of American Medical Association , 277 : 301 – 306 .
   PubMed Web of Science ®Google Scholar
• Clavel , F. and Hance , A.J. 2004 . HIV Drug Resistance . New England Journal of Medicine , 350 : 1023 – 1035 .
   PubMed Web of Science ®Google Scholar
• Committee on Safety of Medicines and Medicines Control Agency ( 2002 ) Suspected Adverse Reaction (ADR) Reporting and the Yellow Card Scheme (Guidance Notes for Nurses). Committee on Safety of Medicines and Medicines Control Agency . Accessed 18 September 2005, available at http://www.mca.gov.uk/ourwork/monitorsafequalmed/yellowcard/ycguidancenotes.pdf
   Google Scholar
• DeAngelis , C.D. , Fontanarosa , P.B. and Flanagin , A. 2001 . Reporting Financial Conflicts of Interest and Relationships Between Investigators and Research Sponsors . Journal of American Medical Association , 286 : 89 – 91 .
   PubMed Web of Science ®Google Scholar
• Drucker , P.F. ( 1967 ) The Effective Decision . The Harvard Business Review , January-February (reprint 67105) .
   Google Scholar
• Edwards , I.R. and Biriell , C. 1994 . Harmonisation in Pharmacovigilance . Drug Safety , 10 : 93 – 102 .
   PubMed Web of Science ®Google Scholar
• Egberts , T.C.G. , Smulders , M. , De Koning , F.H. , Meyboom , R.H. and Leufkens , H.G. 1996 . Can Adverse Drug Reactions be Detected Earlier? A Comparison of Reports by Patients and Professionals . British Medical Journal , 313 : 530 – 531 .
   PubMed Web of Science ®Google Scholar
• Einarson , T.R. 1993 . Drug Related Hospital Admissions . The Annals of Pharmacotherapy , 27 : 832 – 840 .
   PubMed Web of Science ®Google Scholar
• Fontanarosa , P.B. , Rennie , D. and DeAngelis , C.D. 2004 . Postmarketing Surveillance—Lack of Vigilance, Lack of Trust . Journal of American Medical Association , 292 : 2647 – 2650 .
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration ( 2005a ) Guidance for Industry: E2E Pharmacovigilance Planning. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research , April. Accessed 18 Sept 2005, available at http://www.fda.gov/cber/gdlns/ichpup.pdf
   Google Scholar
• Food and Drug Administration ( 2005b ) Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemilogic Assessment. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research , March. Accessed 18 September 2005, available at http://www.fda.gov/cber/gdlns/pharmacovig.htm
   Google Scholar
• Food and Drug Administration ( 2005c ) Reviewer Guidance: Evaluating Risks of Drug Exposure in Human Pregnancies. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research , April. Accessed 18 September 2005, available at http://www.fda.gov/cder/guidance/6777fnl.htm
   Google Scholar
• Gaynor , C. ( 2005 ) Structural Injustice and the MDGs: A Critical Analysis of the Zambian Experience . Trócaire Development Review , 57 – 84 .
   Google Scholar
• Government of Republic of Zambia ( 2004 ) The Pharmaceutical Act, 2004 . No 14 of 2004. Government of Republic of Zambia , 91 – 128 .
   Google Scholar
• Government of Republic of Zambia and Ministry of Health ( 2004 ) National Health Strategic Plan 2001–2005, Mid Term Review Report . Ministry of Health, Government of the Republic of Zambia .
   Google Scholar
• Government of Republic of Zambia and Ministry of Health ( 2005 ) Free Antiretroviral Drugs (ARVs) Operational Guidelines for Health Facilities in Zambia . Ministry of Health, Government of the Republic of Zambia .
   Google Scholar
• Hagopian , A. , Ofosu , A. , Fatusi , A. , Biritwum , R. , Essel , A. Hart , L.G. 2005 . The Flight of Physicians from West Africa: Views of African Physicians and Implications for Policy . Social Science and Medicine , 61 : 1750 – 1760 .
   PubMed Web of Science ®Google Scholar
• Hollander , I. 2006 . Viagra's Rise Above Women's Health Issues: An Analysis of the Social and Political Influences on Drug Approvals in the United States and Japan . Social Science and Medicine , 62 : 683 – 693 .
   Google Scholar
• Horton , R. 2001 . Lotronex and the FRD: An Erosion of Integrity . Lancet , 357 : 1544 – 1545 .
   PubMed Web of Science ®Google Scholar
• Huff-Rousselle , M. ( 2005 ) Starting from Scratch in Timor Leste: Establishing a Pharmaceutical and Medical Supplies System in a Post-Conflict Context . The World Bank .
   Google Scholar
• Huff-Rousselle , M. and Kabwe , V. ( 2006 ) Following the Coartem® Trail in Zambia: Anxious Aspirations & Practical Problems in Rolling Back Malaria . Submitted for publication .
   Google Scholar
• Huff-Rousselle , M. , Kabwe , V. and Chikwenya , N. ( 2006 ) Health Sector Reform and Pharmaceutical Supply: A Zambian Case Study . Submitted for publication .
   Google Scholar
• Huff-Rousselle , M. , Kabwe , V. , Nunn , A. and Simooya , O. ( 2005 ) Pharmacovigilance in Zambia Part I: Rationale, Organizational Roles and Responsibilities, and Basic Reporting System. Working document prepared for Technical Pharmacovigilance Working Group . Health Services and Systems Program .
   Google Scholar
• International Society of Drug Bulletins ( 2005 ) ISDB EU: Berlin Declaration on Pharmacovigilance . International Society of Drug Bulletins .
   Google Scholar
• Kaunda , B. ( 2005 , September 9 ) Doctors’ Go-Slow Continues . Zambia Daily Mail , 1 .
   Google Scholar
• Khoo , S. , Back , D. and Winstanley , P. 2005 . The Potential for Interactions Between Antimalarial and Antiretroviral Drugs . AIDS , 19 : 995 – 1005 .
   PubMed Web of Science ®Google Scholar
• Kombe , G. , Galaty , D. , Mtonga , V. and Banda , P. ( 2005 ) Human Resources Crisis in the Zambian Health System: A Call for Urgent Action. Abt Associates , PHRplus Project, Order No. TE 071 .
   Google Scholar
• Krasner , J. ( 2002 , March 20 ) FDA Rule Changes in Contention Benefits, Dangers of Shorter Drug Review at Center of Debate . The Boston Globe , D1 .
   Google Scholar
• Lasser , K.E. , Allen , P.D. , Woolnahdler , S.J. , Himmelstein , D.U. , Wolfe , S.M. and Bor , D.H. 2002 . Timing of New Black Box Warnings and Withdrawals for Prescription Medications . Journal of American Medical Association , 287 : 2215 – 2220 .
   PubMed Web of Science ®Google Scholar
• Lazarou , J. , Pomeraz , B.H. and Corey , P.N. 1998 . Incidence of Adverse Drug Reactions in Hospitalized Patients, A Meta Analysis of Prospective Studies . Journal of American Medical Association , 279 : 1200 – 1205 .
   PubMed Web of Science ®Google Scholar
• Lenzer , J. 2004 . FDA is Incapable of Protecting US ‘Against Another Vioxx’ . British Medical Journal , 329 : 1253
   PubMed Web of Science ®Google Scholar
• Lindquist , M. ( 2004 , May ) The WHO Adverse Reaction Database . Uppsala Monitoring Centre .
   Google Scholar
• Malenga , G. , Palmer , A. , Staedke , S. , Kazadi , W. , Mutabingwa , T. , Ansah , E. , et al. . (2005) Antimalarial Treatment with Artemisinin Combination Therapy in Africa . British Medical Journal , 331 , 706 – 707 .
   Google Scholar
• Medicines Control Council ( 2004 ) Adverse Drug Reactions Reporting Form . Department of Health, Republic of South Africa. Document: 6.04 ARF1 May 03 v2.doc .
   Google Scholar
• Meyboom , R.H.B. , Egberts , A.C.G. , Gribnau , F.W.J. and Hekster , Y.A. 1999 . Pharmacovigilance in Perspective . Drug Safety , 21 : 429 – 447 .
   PubMed Web of Science ®Google Scholar
• Meyboom , R.H.B. , Lindquist , M. and Egberts , A.C.G. 2000 . An ABC of Drug Related Problems . Drug Safety , 22 : 415 – 423 .
   PubMed Web of Science ®Google Scholar
• Ministry of Health ( 2005 ) Medium-Term Procurement Plan 2005–2007 . Ministry of Health , Lusaka, , Zambia .
   Google Scholar
• Moore , N.D. , Lecointre , D. , Noblet , C. and Mabille , M. 1998 . Frequency and Cost of Serious Adverse Drug Reactions in a Department of General Medicine . British Journal of Clinical Pharmacology , 45 : 301 – 308 .
   PubMed Web of Science ®Google Scholar
• Pirmohamed , M. , Breckenridge , A.M. , Kitteringham , N.R. and Park , B.K. 1998 . Adverse Drug Reactions . British Medical Journal , 316 : 1295 – 1298 .
   PubMed Web of Science ®Google Scholar
• Psaty , B.M. , Furberg , C.D. , Ray , W.A. and Weiss , N.S. 2004 . Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis . Journal of American Medical Association , 292 : 2622 – 2631 .
   PubMed Web of Science ®Google Scholar
• Roberts , P. ( 1994 ) Adverse Drug Reactions (ADRs). A Distance Learning Pack for Community Pharmacists . Centre for Pharmacy Postgraduate Education .
   Google Scholar
• Sasich , L.D. ( 2000 , September 15 ) Comments before the FDA's Public Meeting on the Prescription Drug User Fee Act (PDUFA) . Public Citizen's Health Research Group .
   Google Scholar
• Simooya , O. 2005 . The WHO ‘Roll Back Malaria Project’ Planning for Adverse Event Monitoring in Africa . Drug Safety , 28 : 277 – 286 .
   PubMedGoogle Scholar
• United Nations Development Programme ( 2004 ) Human Development Report 2004: Cultural Liberty in Today's Diverse World . United Nations Development Programme .
   Google Scholar
• Uppsala Monitoring Centre and World Health Organization ( 2000 ) Safety Monitoring of Medical Products: Guidelines for Setting up and Running a Pharmacovigilance Centre . Uppsala Monitoring Centre and the World Health Organization .
   Google Scholar
• Uppsala Monitoring Centre and World Health Organization ( 2002 ) The Importance of Pharmacovigilance: Safety Monitoring of Medical Products . Uppsala Monitoring Centre and the World Health Organization .
   Google Scholar
• Uppsala Monitoring Centre and World Health Organization ( 2006 ) WHO Programme. Uppsala Monitoring Centre and the World Health Organization . Accessed 25 August 2006, available at http://www.who-umc.org/DynPage.aspx?id=13140&mn=1514#4
   Google Scholar
• Wayne , A.W. and Stein , C.M. 2006 . Reform of Drug Regulation—Beyond an Independent Drug-Safety Board . New England Journal of Medicine , 354 : 194 – 201 .
   Google Scholar
• Whittington , C.J. , Kendall , T. , Fonagy , P. , Cottrell , D. , Cotgrove , A. and Boddington , E. 2004 . Selective Serotonin Reuptake Inhibitors in Childhood Depression: Systematic Review of Published versus Unpublished Data . Lancet , 363 : 1341 – 1345 .
   PubMed Web of Science ®Google Scholar
• Willman , D. ( 2000 , December 20 ) How a New Policy Led to Seven Deadly Drugs . Los Angeles Times , p. 1 .
   Google Scholar
• Wong , I.C.K. 1999 . Pharmacovigilance Resources in the United Kingdom . Pharmaceutical Journal , 7059 : 285 – 288 .
   Google Scholar
• World Health Organization ( 1998 ) Report on the International Workshop on Counterfeit Drugs . World Health Organization, 26–28 November, WHO/DRS/CDF/98.1
   Google Scholar
• World Health Organization ( 2002 ) The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products . World Health Organization .
   Google Scholar
• World Health Organization ( 2004a ) The Selection and Use of Essential Medicines. Report of the WHO Expert Committee, 2003 . World Health Organization, WHO Technical Report Series No. 920 .
   Google Scholar
• World Health Organization ( 2004b ) Malaria and HIV Interactions and their Implications for Public Health Policy. Report of Technical Consultation. World Health Organization . Department of HIV/AIDS and Roll Back Malaria Department .
   Google Scholar